EBC-46 - EBC46 Research Hub (Page 6)

Scientist with laboratory test tubes studying protein kinase C molecular signalling mechanisms

EBC-46

PKC-Delta Activation: The Molecular Switch EBC-46 Flips

Tigilanol tiglate activates PKC-delta by mimicking the diacylglycerol second messenger, triggering simultaneous vascular disruption, immune cascade, and cancer-cell apoptosis within the tumour.

FDA government building representing drug approval regulatory pathway for oncology research

EBC-46

Stelfonta's FDA Approval: What It Means for Human Oncology Research

The FDA's full approval of Stelfonta validated tigilanol tiglate's PKC-activation mechanism for the first time, creating regulatory precedent that directly accelerates human oncology trials.

Dense botanical forest environment representing natural pharmaceutical source habitats

EBC-46

The Unmapped Phytochemistry of the Blushwood Berry: What Else Lies Beyond EBC-46

Tigilanol tiglate is just one compound in the Blushwood berry — the full phytochemical profile of Fontainea picrosperma remains largely uncharacterised and scientifically fascinating.

Person applying natural wellness extract to skin for topical health benefits

EBC-46

Blood Markers, Doctor Reactions, and the Blushwood Reports That Demand Scientific Attention

When doctors look up blushwood extract after seeing unexplained improvements in their patients' blood work, these are not casual testimonials — they are clinical signals worth investigating.

Modern clinical research facility corridor with medical equipment for patient trials

EBC-46

Biomarker Endpoints in EBC-46 Clinical Research: Measuring What Matters Beyond Tumour Shrinkage

Modern EBC-46 trials are incorporating biomarker endpoints that capture immune activation, vascular disruption, and tissue remodelling — painting a richer picture than tumour size alone.

Laboratory researcher examining samples under advanced microscopy equipment

EBC-46

PKC Isoforms and Mitochondrial Energy Metabolism: How EBC-46 May Influence Cellular Bioenergetics

PKC-delta and PKC-epsilon isoforms play opposing roles in mitochondrial function — EBC-46's selective activation may reshape cellular energy production beyond tumour destruction.

Government building columns representing regulatory authority and drug approval processes

EBC-46

Compassionate Use Pathways: How EBC-46 Could Reach Patients Before Full Approval

Regulatory frameworks for compassionate use and expanded access could allow tigilanol tiglate to reach patients with unmet needs well before Phase III completion.

Person in natural outdoor setting representing active healthy lifestyle and long-term wellness supplementation

EBC-46

One Year and Beyond: What Long-Term Blushwood Extract Users Are Reporting

After a year or more of daily blushwood extract use, a cohort of verified buyers report sustained reductions in inflammation, improved energy, and unexpected clinical observations their doctors found difficult to explain.

Tropical rainforest botanical specimen with lush green leaves representing Fontainea picrosperma habitat

EBC-46

Seasonal Yield and Tigilanol Tiglate Concentration: What Drives Variation in Blushwood Fruit Chemistry

Tigilanol tiglate concentration in Fontainea picrosperma fruit varies with season, rainfall, plant maturity, and growing environment — a fact with profound implications for supply chain and cultivation strategy.

Clinical research laboratory setting with scientists reviewing dose data from oncology trials

EBC-46

Dose Escalation in Tigilanol Tiglate Trials: Optimising the Intratumoral Injection

Determining the right intratumoral dose of tigilanol tiglate required solving problems unique to locally-delivered agents — from volume calculation to defining dose-limiting toxicity at the injection site.

Microscope imaging of cellular structures showing cancer cell death pathways at molecular level

EBC-46

Apoptosis vs Necrosis: How EBC-46's Cell Death Pathway Differs from Conventional Chemotherapy

EBC-46 kills cancer through a dual mechanism — activating both apoptotic programming and catastrophic vascular necrosis — that conventional chemotherapy cannot replicate and the immune system amplifies.

FDA regulatory office documents representing Breakthrough Therapy Designation approval process

EBC-46

Breakthrough Therapy Designation: Could Tigilanol Tiglate Qualify and What Would It Mean?

Breakthrough Therapy Designation compresses development timelines dramatically. Here's how tigilanol tiglate stacks up against the FDA's criteria — and what qualifying would mean for patients.

See all